Dept of pharma wants review of FDI rules

The department of pharmaceuticals (DoP) under the ministry of chemicals and fertilisers has proposed that the government set up an expert group to assess the impact of foreign direct investment (FDI) in this sector. The move follows complaints from Indian companies that they were being forced to sell out to foreign companies for lack of long-term funding for R&D and market development.

DoP’s proposal comes after a suggestion by the National Security Council (NSC) that the sector be put on a “sensitive list” requiring approval by the Foreign Investment Promotion Board (FIPB).

Currently, FDI up to 100 per cent is allowed in the drugs and pharmaceuticals on the automatic route.

The department was responding to a note prepared by the NSC in February for the 20-member committee of secretaries (CoS) set up to suggest changes in FDI policy in sectors that involve security concerns. Cabinet Secretary K M Chandrasekhar heads the CoS.
 

PEP PILLS KEY PHARMA DEALS IN INDIA
Date	Buyer	Company
2008
Jun	Daiichi Sankyo Co Ltd Japan	Ranbaxy Laboratories Dabur Pharma
Aug	Fresenius Kabi AG  Germany
2009
Jun	Pfizer (Animal Health  Business) US	Vetnex Animal Health Ltd  (earlier ICICI Venture acquired from Ranbaxy)
Jun	Vetoquinol SA  France	Wockhardt  (Animal Care subsidiary)
Jul	Abbott Laboratories  US	Wockhardt  (Nutrition business)
Jul	Sanofi Aventis  France through  Merieux Alliance	Shanta Biotech  (raised stake from  60 to 80%)

In its letter to the NSC, the DoP said it had already raised concerns with the commerce ministry that acquisitions of Indian companies in this sector could increase, and this trend would impact the pricing and availability of medicines in India. It has suggested that an appropriate assessment be made on this issue by a small group and a study commissioned quickly. The DoP has proposed that the recommendations could be placed before the Prime Minister’s Economic Advisory Council or any other competent authority.

It has said the study should consider the views of the department of biotechnology, under the ministry of science and technology, and the ministry of family health and family welfare before the CoS takes a final call on changes in FDI for this sector.

In response to NSC’s February note, the commerce ministry has suggested that FDI levels in the sector on the automatic route should be cut from 100 to 49 per cent, meaning all proposals for foreign investment above 49 per cent would need FIPB approval.

The Indian Pharmaceutical Alliance – an association of Indian pharma companies -has been lobbying the government on the serious funding problems the sector faces, pointing out that companies like Ranbaxy, which was recently acquired by foreign companies, was involved in R&D and was striving for development of international business. However both these activities required significant infusion of funds from time to time with long-gestation periods.

The Alliance has also pointed out that there are serious new entry barriers in the international market such as seizure in transit, ever-growing intellectual property rights enforcement and protection and attacks on India’s brand equity.

The Alliance has suggested that government should consider appropriate funding mechanism to protect and promote the domestic pharma industry.